BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $65
CG Oncology Is Maintained at Buy by B of A Securities
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
Buy Rating Affirmed for CG Oncology Amidst Bladder Cancer Market Opportunities
BofA Securities Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $65
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
RBC Capital Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $66
RBC Initiates CG Oncology at Outperform, Speculative Risk With $66 Price Target
CG Oncology Analyst Ratings
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $75
Buy Rating Justified for CG Oncology's Cretostimogene Due to Superior Safety Profile and Competitive Efficacy
Goldman Sachs Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $52
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
Buy Rating Affirmed for CG Oncology Amid Competitive Landscape and Strong Clinical Results
CG Oncology Analyst Ratings
Morgan Stanley Keeps Their Buy Rating on CG Oncology, Inc. (CGON)
Buy Rating for CG Oncology: Promising CG0070 Data Signals Strong Market Potential
Analysts' Opinions Are Mixed on These NA Stocks: Solventum Corporation (SOLV) and CG Oncology, Inc. (CGON)
CG Oncology Analyst Ratings
Analysts Are Bullish on Top NA Stocks: Viking Holdings Ltd (VIK), CG Oncology, Inc. (CGON)